Rofecoxib	0	9	B-Drug_or_compound
as	10	12	O
adjunctive	13	23	O
therapy	24	31	O
for	32	35	O
haemophilic	36	47	O
arthropathy	48	59	O
.	59	60	O

Joint	62	67	B-Multi-tissue_structure
haemorrhage	68	79	O
and	80	83	O
subsequent	84	94	O
haemophilic	95	106	O
arthropathy	107	118	O
are	119	122	O
significant	123	134	O
complications	135	148	O
in	149	151	O
haemophilia	152	163	O
.	163	164	O

The	165	168	O
pathophysiology	169	184	O
involves	185	193	O
inflammation	194	206	O
and	207	210	O
angiogenesis	211	223	O
.	223	224	O

Cyclooxygenase	225	239	B-Gene_or_gene_product
-	239	240	I-Gene_or_gene_product
2	240	241	I-Gene_or_gene_product
(	242	243	O
COX	243	246	B-Gene_or_gene_product
-	246	247	I-Gene_or_gene_product
2	247	248	I-Gene_or_gene_product
)	248	249	O
inhibitors	250	260	O
are	261	264	O
anti	265	269	O
-	269	270	O
inflammatory	270	282	O
agents	283	289	O
,	289	290	O
which	291	296	O
have	297	301	O
potent	302	308	O
anti	309	313	O
-	313	314	O
inflammatory	314	326	O
,	326	327	O
anti	328	332	O
-	332	333	O
angiogenic	333	343	O
and	344	347	O
analgesic	348	357	O
properties	358	368	O
yet	369	372	O
do	373	375	O
not	376	379	O
affect	380	386	O
platelet	387	395	B-Cell
function	396	404	O
in	405	407	O
the	408	411	O
manner	412	418	O
of	419	421	O
traditional	422	433	O
non	434	437	B-Drug_or_compound
-	437	438	I-Drug_or_compound
steroidal	438	447	I-Drug_or_compound
anti	448	452	I-Drug_or_compound
-	452	453	I-Drug_or_compound
inflammatory	453	465	I-Drug_or_compound
drugs	466	471	I-Drug_or_compound
.	471	472	O

These	473	478	O
properties	479	489	O
make	490	494	O
such	495	499	O
agents	500	506	O
potentially	507	518	O
useful	519	525	O
as	526	528	O
adjunctive	529	539	O
therapy	540	547	O
in	548	550	O
haemophilia	551	562	O
.	562	563	O

There	564	569	O
is	570	572	O
only	573	577	O
one	578	581	O
prior	582	587	O
report	588	594	O
describing	595	605	O
rofecoxib	606	615	B-Drug_or_compound
treatment	616	625	O
in	626	628	O
a	629	630	O
single	631	637	O
haemophilia	638	649	O
patient	650	657	B-Organism
.	657	658	O

Our	659	662	O
objectives	663	673	O
were	674	678	O
to	679	681	O
determine	682	691	O
the	692	695	O
safety	696	702	O
and	703	706	O
efficacy	707	715	O
of	716	718	O
rofecoxib	719	728	B-Drug_or_compound
in	729	731	O
treating	732	740	O
acute	741	746	O
haemarthrosis	747	760	O
,	760	761	O
chronic	762	769	O
synovitis	770	779	O
,	779	780	O
target	781	787	O
joints	788	794	B-Multi-tissue_structure
and	795	798	O
pain	799	803	O
.	803	804	O

We	805	807	O
conducted	808	817	O
a	818	819	O
retrospective	820	833	O
medical	834	841	O
record	842	848	O
review	849	855	O
of	856	858	O
patients	859	867	B-Organism
treated	868	875	O
with	876	880	O
rofecoxib	881	890	B-Drug_or_compound
for	891	894	O
acute	895	900	O
haemarthrosis	901	914	O
,	914	915	O
chronic	916	923	O
synovitis	924	933	O
,	933	934	O
target	935	941	O
joint	942	947	B-Multi-tissue_structure
or	948	950	O
pain	951	955	O
.	955	956	O

The	957	960	O
safety	961	967	O
and	968	971	O
efficacy	972	980	O
of	981	983	O
rofecoxib	984	993	B-Drug_or_compound
treatment	994	1003	O
were	1004	1008	O
determined	1009	1019	O
based	1020	1025	O
on	1026	1028	O
subjective	1029	1039	O
patient	1040	1047	B-Organism
reports	1048	1055	O
and	1056	1059	O
physical	1060	1068	O
examinations	1069	1081	O
during	1082	1088	O
follow	1089	1095	O
-	1095	1096	O
up	1096	1098	O
clinic	1099	1105	O
visits	1106	1112	O
.	1112	1113	O

A	1114	1115	O
total	1116	1121	O
of	1122	1124	O
28	1125	1127	O
patients	1128	1136	B-Organism
between	1137	1144	O
3	1145	1146	O
and	1147	1150	O
37	1151	1153	O
years	1154	1159	O
of	1160	1162	O
age	1163	1166	O
were	1167	1171	O
treated	1172	1179	O
for	1180	1183	O
a	1184	1185	O
total	1186	1191	O
of	1192	1194	O
42	1195	1197	O
courses	1198	1205	O
of	1206	1208	O
rofecoxib	1209	1218	B-Drug_or_compound
treatment	1219	1228	O
.	1228	1229	O

All	1230	1233	O
courses	1234	1241	O
were	1242	1246	O
evaluated	1247	1256	O
for	1257	1260	O
safety	1261	1267	O
and	1268	1271	O
31	1272	1274	O
for	1275	1278	O
efficacy	1279	1287	O
.	1287	1288	O

Rofecoxib	1289	1298	B-Drug_or_compound
was	1299	1302	O
used	1303	1307	O
for	1308	1311	O
eight	1312	1317	O
acute	1318	1323	O
haemarthrosis	1324	1337	O
,	1337	1338	O
four	1339	1343	O
target	1344	1350	O
joints	1351	1357	B-Multi-tissue_structure
,	1357	1358	O
seven	1359	1364	O
cases	1365	1370	O
of	1371	1373	O
synovitis	1374	1383	O
and	1384	1387	O
12	1388	1390	O
episodes	1391	1399	O
of	1400	1402	O
pain	1403	1407	O
.	1407	1408	O

Efficacy	1409	1417	O
was	1418	1421	O
demonstrated	1422	1434	O
particularly	1435	1447	O
for	1448	1451	O
chronic	1452	1459	O
synovitis	1460	1469	O
and	1470	1473	O
pain	1474	1478	O
and	1479	1482	O
no	1483	1485	O
serious	1486	1493	O
adverse	1494	1501	O
events	1502	1508	O
occurred	1509	1517	O
.	1517	1518	O

This	1519	1523	O
is	1524	1526	O
the	1527	1530	O
largest	1531	1538	O
study	1539	1544	O
to	1545	1547	O
date	1548	1552	O
evaluating	1553	1563	O
COX	1564	1567	B-Gene_or_gene_product
-	1567	1568	I-Gene_or_gene_product
2	1568	1569	I-Gene_or_gene_product
inhibitors	1570	1580	O
as	1581	1583	O
adjunctive	1584	1594	O
therapy	1595	1602	O
in	1603	1605	O
haemophilia	1606	1617	O
and	1618	1621	O
suggests	1622	1630	O
that	1631	1635	O
these	1636	1641	O
agents	1642	1648	O
may	1649	1652	O
be	1653	1655	O
an	1656	1658	O
important	1659	1668	O
adjunctive	1669	1679	O
therapy	1680	1687	O
in	1688	1690	O
the	1691	1694	O
management	1695	1705	O
of	1706	1708	O
haemophilia	1709	1720	O
.	1720	1721	O

